RTP Mobile Logo

Altman JK et al. Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Proc ASCO 2017;Abstract 7003.

Amadori S et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: Results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol 2016;34(9):972-9. Abstract

Boddu PC et al. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer 2017;123(16):3050-60. Abstract

Cogle CR et al. Factors influencing first-line therapy of acute myeloid leukemia (AML) patients (pts) in the Connect MDS/AML Disease Registry. Proc ASCO 2018;Abstract 7037.

Cortes JE et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol 2018;93(11):1301-10. Abstract

Cortes J et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 2018;19(7):889-903. Abstract

Davids MS et al. Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL. Proc ASCO 2018;Abstract 7526.

DiNardo CD et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018;378(25):2386-98. Abstract

DiNardo CD et al. Durable response with venetoclax in combination with decitabine or azacitidine in elderly patients with acute myeloid leukemia (AML). Proc ASCO 2018;Abstract 7010.

DiNardo CD et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: A non-randomised, open-label, phase 1b study. Lancet Oncol 2018;19(2):216-28. Abstract

Jabbour E et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: A phase 2 clinical trial. JAMA Oncol 2018;4(2):230-4. Abstract

Kantarjian H et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: A single-arm, phase 2 study. Lancet Oncol 2018;19(2):240-8. Abstract

Kantarjian H et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017;376(9):836-47. Abstract

Lancet JE et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36(26):2684-92. Abstract

Perl AE et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: A multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol 2017;18(8):1061-75. Abstract

Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood 2017;129(12):1627-35. Abstract

Savona MR et al. Phase Ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS. Clin Cancer Res 2018;24(10):2294-303. Abstract

Shah BD et al. Outcomes of patients treated with prior blinatumomab in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients with R/R ALL. Proc ASCO 2018;Abstract 7006.

Stein EM et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 2019;133(7):676-87. Abstract

Stein EM et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017;130(6):722-31. Abstract

Stevens BM et al. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. Nat Commun 2018;9(1):3694. Abstract

Stone RM et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017;377(5):454-64. Abstract

Zhu HH et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: A non-inferiority, randomised phase 3 trial. Lancet Oncol 2018;19(7):871-9. Abstract